As summarized in Figure 10, our findings supply hard evidence that GZFL has shown promising therapeutic effects on memory impairment and synaptic dysfunction in AD, which are due to the inhibition of microglial activation and neuroinflammation via obstruction of JAK2/STAT3 signaling pathway. Here, JAK2 is linked to Alzheimer disease.